Donate For Public and Patients Store Search

F007 - Autoimmune Blistering Diseases: What's New

Friday, March 1; 9:00 AM - 11:00 AM

Learning Objectives

Following this course, the attendee should be able to:

  • Shorten the time to diagnose a blistering disease
  • Recognize if certain drugs may have triggered the disease to cease them
  • Select the best treatment for the patient with pemphigus and pemphigoid.

Description

This forum will provide novel information on why certain patients are more likely genetically to develop pemphigus, EBA and MMP and what environmental threats trigger pemphigoid. The latest treatments will be reviewed for pemphigus and pemphigoid.

Disclosures

  • Caux, Frederic, PhD: LEO Laboratories Ltd (LEO Pharma) – I(Fees); Novartis – A(H); Pierre Fabre Dermatologie – C(H); Principia Biopharma Inc – A(H), I(Fees); Roche Laboratories – I(Fees);
  • Joly, Pascal, MD, PhD: Almirall – C(H); GlaxoSmithKline – C(H); Lilly ICOS LLC – C(H); Novartis Pharmaceuticals Corp. – C(H); Principia Biopharma Inc – C(H); Roche Laboratories – C(H); sanofi-aventis – C(H);
  • Korman, Neil J., MD, PhD: AbbVie – I(Grants/Research Funding), SP(H); Celgene – C(H); Celgene Corporation – A(H), I(Grants/Research Funding); Chugai Pharmaceutical Co., Ltd. – I(Grants/Research Funding); Dr Reddy's Laboratory – A(Fees), C(Fees); Eli Lilly and Company – A(H), I(Grants/Research Funding); Genentech, Inc. – A(H); GlaxoSmithKline – A(H); Immune Pharmaceuticals – A(Fees); Janssen Pharmaceuticals, Inc – A(H), O(Grants/Research Funding); Kyowa Hakko Kirin Pharma, Inc. – I(Grants/Research Funding); LEO Laboratories Ltd (LEO Pharma) – I(Grants/Research Funding); Menlo Therapeutics – I(Grants/Research Funding); Merck & Co., Inc. – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), C(H); Pfizer Inc. – A(H), I(Grants/Research Funding); Principia Biopharma Inc. – A(H); Prothena – I(Grants/Research Funding); Regeneron Pharmaceuticals, Inc. – A(Fees), I(Grants/Research Funding); Rhizen Pharmaceuticals S.A. – I(Grants/Research Funding); Sanofi – A(Fees), C(H); Sun Pharmaceutical Industries Ltd. – A(Fees); Syntimmune, Inc. – I(Grants/Research Funding); Trevi Therapeutics – I(Grants/Research Funding); UCB – I(Grants/Research Funding); Valeant Pharmaceuticals International – A(Fees);
  • Murrell, Dedee F., MD: 3M Pharmaceuticals – C(Grants/Research Funding); Abbott Laboratories – A(H), SP(H); AbbVie – I(Grants/Research Funding); Actavis – Speaker/Faculty Education(H); Almirall – C(H); Amgen – I(Fees); Amicus Therapeutics – A(H); Anacor Pharmaceuticals, Inc. – I(Grants/Research Funding); Ascent Pharmaceuticals – SP(H); Castle Creek Pharmaceuticals – C(Fees); CSL – SP(Grants/Research Funding), SP(H); Delfin Technology – I(EQ); Eli Lilly and Company – A(H); Galderma Laboratories, L.P. – I(Grants/Research Funding), I(OB); Janssen-Ortho Inc. – O(Grants/Research Funding); Leo Pharma Inc – Speaker/Faculty Education(H); Medimmune – I(Grants/Research Funding); Merck Serono – I(Fees), I(Grants/Research Funding); Molynlycke – SP(Grants/Research Funding); Novartis Pharmaceuticals Corp. – A(H), I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Pierre Fabre Dermo-Cosmétique US – SP(H); Principia Biopharma Inc – C(H); Roche Laboratories – A(H), I(Grants/Research Funding); Samumed, LLC – I(Grants/Research Funding); Schering-Plough Corporation – I(Grants/Research Funding), SP(OB); Shire – A(H), I(Grants/Research Funding); Stiefel a GSK company – SP(H); XOMA (US) LLC – I(Grants/Research Funding);
  • Sprecher, Eli, MD, PhD: no financial relationships exist with commercial interests.
  • Tasanen, Kaisa, MD, PhD: no financial relationships exist with commercial interests.
Schedule
Friday, March 1
9:00 AM
Dr. Sprecher / Pemphigus, who gets it and why?
9:25 AM
Dr. Caux / Epidermolysis bullosa acquisita & MMP- who gets it and why?
9:40 AM
Dr. Tasanen / Bullous pemphigoid- who gets it and why?
10:00 AM
Dr. Joly / Methotrexate for bullous pemphigoid
10:20 AM
Dr. Korman / New therapies for bullous pemphigoid
10:40 AM
Dr. Murrell / New therapies in the pipeline for pemphigus
Event Details
  • Date
    Friday, March 1
  • Time
    9:00 AM - 11:00 AM
  • Location
    Room 146C
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Dedee F. Murrell, MD, FAAD
Speakers
  • Eli Sprecher, MD, PhD
  • Frederic Caux, PhD
  • Kaisa Tasanen, MD, PhD
  • Neil J. Korman, MD, PhD, FAAD
  • Pascal Joly, MD, PhD